Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.
作者信息
Chastre Anne, Hafler David A, O'Connor Kevin C
机构信息
Yale School of Medicine, New Haven, CT
出版信息
N Engl J Med. 2016 Apr 14;374(15):1495-6. doi: 10.1056/NEJMc1513302.
Abstract
摘要
相似文献
1
Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.KIR4.1作为多发性硬化症免疫靶点的评估
N Engl J Med. 2016 Apr 14;374(15):1495-6. doi: 10.1056/NEJMc1513302.
2
Multiple Sclerosis and Antibodies against KIR4.1.多发性硬化症与抗KIR4.1抗体
N Engl J Med. 2016 Apr 14;374(15):1496-8. doi: 10.1056/NEJMc1507131.
3
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.抗内向整流钾通道4.1抗体作为多发性硬化可靠标志物未得到证实。
Mult Scler. 2014 Nov;20(13):1699-703. doi: 10.1177/1352458514531086. Epub 2014 Apr 22.
4
Low reliability of anti-KIR4.1 peptide auto-antibodies in multiple sclerosis patients.抗 KIR4.1 肽自身抗体在多发性硬化症患者中的可靠性低。
Mult Scler. 2018 Jun;24(7):910-918. doi: 10.1177/1352458517711275. Epub 2017 May 26.
5
Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?多发性硬化症中内向整流钾通道4.1抗体：不同方法——结果相互矛盾？
Mult Scler. 2015 Apr;21(5):537-9. doi: 10.1177/1352458514564493. Epub 2015 Jan 12.
6
Potassium channel KIR4.1 as an immune target in multiple sclerosis.钾通道 KIR4.1 作为多发性硬化症的免疫靶点。
N Engl J Med. 2012 Jul 12;367(2):115-23. doi: 10.1056/NEJMoa1110740.
7
Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.多发性硬化症患者中钾通道KIR4.1抗体的检测
J Immunol Methods. 2017 Jun;445:53-58. doi: 10.1016/j.jim.2017.03.008. Epub 2017 Mar 12.
8
Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?多发性硬化症中抗KIR4.1抗体增加：它可能是疾病复发的标志物吗？
Mult Scler. 2015 Apr;21(5):572-9. doi: 10.1177/1352458514551779. Epub 2014 Nov 12.
9
Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease.获得性脱髓鞘中枢神经系统疾病患儿的钾离子通道 KIR4.1 特异性抗体。
Neurology. 2014 Feb 11;82(6):470-3. doi: 10.1212/WNL.0000000000000097. Epub 2014 Jan 10.
10
Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.多发性硬化症中的抗Kir4.1抗体：特异性与致病性
Int J Mol Sci. 2020 Dec 17;21(24):9632. doi: 10.3390/ijms21249632.
引用本文的文献
1
Roles of Ion Channels in Oligodendrocyte Precursor Cells: From Physiology to Pathology.离子通道在少突胶质前体细胞中的作用：从生理到病理
Int J Mol Sci. 2025 Jul 29;26(15):7336. doi: 10.3390/ijms26157336.
2
Multiple sclerosis: an immune attack on astrocyte-mediated ion and water homeostasis.多发性硬化症：对星形胶质细胞介导的离子和水平衡的免疫攻击。
Nat Rev Neurol. 2025 May;21(5):283-289. doi: 10.1038/s41582-025-01081-y. Epub 2025 Apr 4.
3
A Blood Test for the Diagnosis of Multiple Sclerosis.多发性硬化症的血液检测。
Int J Mol Sci. 2024 Jan 30;25(3):1696. doi: 10.3390/ijms25031696.
4
Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines.来自多发性硬化症患者血清和脑脊液的抗体与少突胶质细胞系和神经元细胞系结合。
Brain Commun. 2023 May 23;5(3):fcad164. doi: 10.1093/braincomms/fcad164. eCollection 2023.
5
An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.多发性硬化症诊断实验室生物标志物的最新进展。
Curr Neurol Neurosci Rep. 2022 Oct;22(10):675-688. doi: 10.1007/s11910-022-01227-1. Epub 2022 Oct 21.
6
Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.多发性硬化症中的致病性自身抗体——从一个简单的想法到一个复杂的概念。
Nat Rev Neurol. 2022 Nov;18(11):681-688. doi: 10.1038/s41582-022-00700-2. Epub 2022 Aug 15.
7
Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.多发性硬化症中的抗Kir4.1抗体：特异性与致病性
Int J Mol Sci. 2020 Dec 17;21(24):9632. doi: 10.3390/ijms21249632.
8
B cells in autoimmune and neurodegenerative central nervous system diseases.自身免疫性和神经退行性中枢神经系统疾病中的 B 细胞。
Nat Rev Neurosci. 2019 Dec;20(12):728-745. doi: 10.1038/s41583-019-0233-2. Epub 2019 Nov 11.
9
Biomarkers in Multiple Sclerosis.多发性硬化症中的生物标志物。
Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a029058. doi: 10.1101/cshperspect.a029058.
10
The tension between early diagnosis and misdiagnosis of multiple sclerosis.多发性硬化症早期诊断与误诊之间的矛盾关系。
Nat Rev Neurol. 2017 Sep;13(9):567-572. doi: 10.1038/nrneurol.2017.106. Epub 2017 Aug 11.
本文引用的文献
1
Multiple Sclerosis and Antibodies against KIR4.1.多发性硬化症与抗KIR4.1抗体
N Engl J Med. 2016 Apr 14;374(15):1496-8. doi: 10.1056/NEJMc1507131.
2
Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.多发性硬化症中对多种自身免疫性疾病相关抗原的体液免疫反应。
PLoS One. 2015 Jun 11;10(6):e0129503. doi: 10.1371/journal.pone.0129503. eCollection 2015.
3
Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?多发性硬化症中内向整流钾通道4.1抗体：不同方法——结果相互矛盾？
Mult Scler. 2015 Apr;21(5):537-9. doi: 10.1177/1352458514564493. Epub 2015 Jan 12.
4
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.将KIR4.1钾通道作为多发性硬化症患者潜在抗原的研究：一项比较研究。
Lancet Neurol. 2014 Aug;13(8):795-806. doi: 10.1016/S1474-4422(14)70141-3. Epub 2014 Jul 6.
5
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.抗内向整流钾通道4.1抗体作为多发性硬化可靠标志物未得到证实。
Mult Scler. 2014 Nov;20(13):1699-703. doi: 10.1177/1352458514531086. Epub 2014 Apr 22.
6
Potassium channel KIR4.1 as an immune target in multiple sclerosis.钾通道 KIR4.1 作为多发性硬化症的免疫靶点。
N Engl J Med. 2012 Jul 12;367(2):115-23. doi: 10.1056/NEJMoa1110740.
Zotero 插件